This article needs additional citations for verification .(October 2021) |
| | |
| | |
| Clinical data | |
|---|---|
| Trade names | Remodulin, Orenitram, Tyvaso, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622038 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous, intravenous, inhalation, by mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ~100% |
| Metabolism | Substantially metabolized by the liver |
| Elimination half-life | 4 hours |
| Excretion | Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.236.149 |
| Chemical and physical data | |
| Formula | C23H34O5 |
| Molar mass | 390.520 g·mol−1 |
| |
| | |
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. [7]
Treprostinil was approved for use in the United States in May 2002. [8]
Treprostinil is indicated for the treatment of pulmonary arterial hypertension in people with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. [1]
Treprostinil inhalation solution and treprostinil inhalation powder are indicated for the treatment of people with pulmonary arterial hypertension (WHO Group 1) to improve exercise ability; and people with pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability. [3] [4]
In the European Union, treprostinil (Trepulmix) is indicated for the treatment of adults with WHO Functional Class III or IV and inoperable chronic thromboembolic pulmonary hypertension; [6] or persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment to improve exercise capacity. [6]
Common side effects depending on route of administration:
In 1976, the first paper on prostacyclin was published. [10]
Treprostinil (Remodulin) was approved for medical use in the United States in May 2002, [8] and again in July 2018. [11]
Treprostinil (Tyvaso), as inhalation solution, was approved for medical use in the United States in July 2009, [12] and again in April 2021. [13]
Treprostinil (Orenitram), as extended release tablets, was approved for medical use in the United States in December 2013. [14]
Treprostinil (Trepulmix) was authorized for medical use in the European Union in April 2020. [6] Trepulmix is a hybrid medicine that is similar to the reference medicine Remodulin. [6] It contains the same active substance, but it is used for treating a different form of pulmonary hypertension. [6]
Treprostinil (Tyvaso DPI), as inhalation powder, was approved for medical use in the United States in May 2022. [15] [16]
Treprostinil (Yutrepia), as inhalation powder, was approved for medical use in the United States in June 2025. [5] [17] [18]
Treprostinil therapy may be effective in treating Degos disease. [19]